Jefferies Stick to Their Buy Rating for Sanofi
Investing.com
Published Oct 21, 2021 05:13AM ET
Jefferies (NYSE:JEF) analyst Peter Welford maintained a Buy rating on Sanofi (NASDAQ:SNY) on Thursday, setting a price target of EUR120, which is approximately 41.95% above the present share price of $98.38.
Welford expects Sanofi to post earnings per share (EPS) of $0.49 for the fourth quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Sanofi, with an average price target of $119.86.
The analysts price targets range from a high of $139.64 to a low of $93.1.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $9.05 billion and a net profit of $1.87 billion. The company's market cap is $123.95 billion.
According to TipRanks.com, Jefferies analyst Peter Welford is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.1% and a 61.86% success rate.
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.